A recent study found that stopping GLP-1s, such as Ozempic or Wegovy, can reverse the cardiovascular benefits they provide
The 2024 Journal of Cosmetic Dermatology commentary by Andriotis and Dayan (PMC11845967) explicitly recommended this combination approach, noting that effective management of facial volume loss, skin laxity, and body contour challenges following GLP-1 weight loss requires a combination of injectable treatments, energy-based devices, and in some cases surgical interventions
It also has antibacterial activity and it plays a role in appetite suppression
Drug-induced hyponatremia associated with sodium-glucose cotransporter 2 inhibitors, immune checkpoint inhibitors, and targeted anticancer agents
Precise phenobarbital dosing can be achieved by serially monitoring phenobarbital trough levels (e.g., q12hr or q24hr)